Quarterly ResultAug 10, 2026, 07:36 AM
Silence Therapeutics Q2 Net Loss $12.3M; Cash $72.1M
AI Summary
Silence Therapeutics reported a net loss of $12.3 million for Q2 2026 and $27.2 million for the first half of 2026. The company's cash and cash equivalents stood at $72.1 million as of June 30, 2026, which it believes is sufficient to fund operations into 2028. Operating loss and net cash used in operations decreased significantly compared to the prior year, despite zero revenue in Q2 2026.
Key Highlights
- Net Loss for Q2 2026 was $12.3 million, down from $27.4 million in Q2 2025.
- Net Loss for H1 2026 was $27.2 million, down from $55.9 million in H1 2025.
- Cash and cash equivalents totaled $72.1 million as of June 30, 2026.
- Operating loss for Q2 2026 was $13.9 million, a decrease from $24.0 million in Q2 2025.
- Net cash used in operations for H1 2026 was $14.1 million, down from $34.1 million in H1 2025.
- Revenue for Q2 2026 was $0, compared to $0.2 million in Q2 2025.
- Company expects current cash to fund operations into 2028.
Price Impact
More from SLN